%0 Journal Article
%T Efficacy and Safety of Sacubitril/valsartan in Patients with Heart Failure
%A Waleed Alhabeeb
%A Fakhr AlAyoubi
%A Ahmad Hayajneh
%A Fayez Elshaer
%J International Journal of Pharmaceutical Research and Allied Sciences
%@ 2277-3657
%D 2020
%V 9
%N 4
%P 11-18
%X Objective: Clinical trial data on sacubitril/valsartan are important. Considering that real-world data have important clinical implications, we aimed to report the efficacy and safety of sacubitril/valsartan in patients with heart failure (HF) in Saudi Arabia.Methods: This was a pilot prospective clinical trial consisting of adult patients (≥18 years old) with HF (left ventricular ejection fraction [EF] ≤40%) who were taking angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for at least 1 month before presenting to the clinic and who were eligible for sacubitril/valsartan. Results: A total of 20 patients with a mean age of 60.75 years (range, 33–81 years) were included. At presentation, the majority of the patients presented with New York Heart Association (NYHA) class II symptoms (15/20), EF 
%U https://ijpras.com/article/efficacy-and-safety-of-sacubitrilvalsartan-in-patients-with-heart-failure